Crescent Biopharma Advances CR-001 Combos, Clears CR-002 IND
Crescent Biopharma announced enrollment in CR-001 chemotherapy combination cohorts and IND allowance for CR-002. Initial data are expected in 2027.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.